Rasagiline

Chemical formula: C₁₂H₁₃N  Molecular mass: 171.238 g/mol  PubChem compound: 3052776

Therapeutic indications

Rasagiline is indicated for:

Parkinson's disease

Population group: only adults (18 years old or older)

Rasagiline is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Rasagiline is contraindicated in the following cases:

Severe hepatic impairment, moderate hepatic impairment

at least one of
Hepatic failure stage IV
Hepatic failure stage III

Monoamine oxidase (MAO) inhibitors

Monoamine oxidase inhibitors (MAOIs)

Fluoxetine, fluvoxamine

at least one of
Fluoxetine
Fluvoxamine

Ephedrine, pseudoephedrine

at least one of
Ephedrine
Pseudoephedrine

Dextromethorphan

Demorphan

Pethidine

Pethidine

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: RASAGILINE MYLAN Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈